Stocks and Investing Stocks and Investing
Mon, October 18, 2021
Sun, October 17, 2021
Fri, October 15, 2021
Thu, October 14, 2021
Wed, October 13, 2021
Tue, October 12, 2021

Judah Frommer Maintained (SRPT) at Hold with Increased Target to $100 on, Oct 12th, 2021


Published on 2024-10-27 18:08:01 - WOPRAI, Judah Frommer
  Print publication without navigation


Judah Frommer of Credit Suisse, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Hold with Increased Target from $75 to $100 on, Oct 12th, 2021.

Judah has made no other calls on SRPT in the last 4 months.



There are 4 other peers that have a rating on SRPT. Out of the 4 peers that are also analyzing SRPT, 2 agree with Judah's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $90 on, Monday, August 16th, 2021
  • Anupam Rama of "JP Morgan" Upgraded from Sell to Hold and Decreased Target to $87 on, Thursday, August 5th, 2021


These are the ratings of the 2 analyists that currently disagree with Judah


  • Whitney Ijem of "Guggenheim" Upgraded from Hold to Strong Buy on, Wednesday, September 15th, 2021
  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Decreased Target to $122 on, Thursday, August 5th, 2021